Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company that invents, develops, manufactures, and commercializes medicines aimed at treating serious diseases across multiple therapeutic areas. Valued at a market cap of $59.1 billion, the company is expected to announce its fiscal Q3 earnings for 2025 before the market opens on Tuesday, Oct. 28. Before this event, analysts expect this healthcare company to report a profit of$7.80 per share, down 33.5% from $11.73 per sh ...